Menu
Search
|

Menu

Close
X

Biocept Inc BIOC.OQ (NASDAQ Stock Exchange Capital Market)

7.19 USD
-- (--)
As of Jul 14
chart
Previous Close 7.19
Open --
Volume --
3m Avg Volume 69,184
Today’s High --
Today’s Low --
52 Week High 48.90
52 Week Low 3.50
Shares Outstanding (mil) 30.25
Market Capitalization (mil) 39.03
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.50 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
5
FY16
3
FY15
1
EPS (USD)
FY18
-3.341
FY17
-21.517
FY16
-65.190
FY15
-96.704
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
7.36
5.73
Price to Book (MRQ)
vs sector
5.04
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
19.04
16.72
LT Debt to Equity (MRQ)
vs sector
10.82
12.39
Return on Investment (TTM)
vs sector
-328.01
14.61
Return on Equity (TTM)
vs sector
-550.52
16.34

EXECUTIVE LEADERSHIP

David Hale
Non-Executive Chairman of the Board, Since 2014
Salary: $111,289.00
Bonus: --
Michael Nall
President, Chief Executive Officer, Director, Since 2013
Salary: $362,202.00
Bonus: $101,500.00
Timothy Kennedy
Chief Financial Officer and Senior Vice President of Operations, Since 2016
Salary: --
Bonus: --
Lyle Arnold
Senior Vice President - Research & Development, Chief Scientific Officer, Since 2011
Salary: $261,672.00
Bonus: $59,867.00
Veena Singh
Senior Vice President, Senior Medical Director, Since 2014
Salary: $292,129.00
Bonus: $63,042.00

COMPANY PROFILE

Sector: Healthcare
Industry: Medical Equipment, Supplies & Distribution
Address:

5810 Nancy Ridge Dr Ste 150
SAN DIEGO   CA   92121-2840

Phone: +1858.3208200

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

SPONSORED STORIES